SLC5A2 and chronic kidney disease: During recent large cardiovascular outcome trials (CVOTs), it was observed that SGLT2 inhibitors may also have additional benefits for preventing the development and progression of CKD in people with T2D beyond what could be expected from glucose lowering alone (6, 7, 8).